SPOTLIGHT: Heparin prices double since recalls


Since Baxter recalled virtually all its heparin products on reports of severe reactions and deaths, the price for the blood thinner has doubled. The sole U.S. supplier, APP Pharmaceuticals, says costs for crude Chinese heparin have risen fivefold since last year and recent price increases don't cover all its higher expenses. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.